Department of Medicine

Department of Medicine

  Division of Hematology/Oncology

[Return To Index page]
photo Priya Rastogi, MD

Associate Professor of Medicine

Member, Magee/UPCI Breast Program


Phone: 412-641-3494

Office: Magee-Womens Hospital
300 Halket Street, Room 3524
Pittsburgh, PA 15213
Phone: 412-641-3494
Fax: 412-641-6461
Administrative Assistant:
MaryTeresa Dujmic
Address: 300 Halkett Street
Magee Womens Hospital, Room I 410
Pittsburgh, PA 15213
Phone: 412-641-3494
Fax: 412-641-6461
Education and Training
Bachelor of Arts in Chemistry, Miami University, Oxford, OH, 1993
Doctor of Medicine,, Wright State University, Dayton, OH, 1997
Internal Medicine Residency, Saint Joseph Hospital, Denver, CO, 2000
Hematology/Oncology Fellowship, University of Pittsburgh School of Medicine, 2003
Research Interest
I am involved with the development and implementation of phase II and phase III clinical trials and serve as the protocol officer for phase II and phase III adjuvant and neoadjuvant breast cancer clinical trials. I am a published author in several medical journals including: Journal of Clinical Oncology, Clinical Breast Cancer, New England Journal of Medicine, Oncology, Oncology Nurse Forum, Onkologie, Menopause, and Breast Cancer Research Treatment
Clinical Interest
I am an Associate Professor of Medicine at the University of Pittsburgh, School of Medicine. I also serve as Senior Associate Medical Director and Vice Chair for Medical Affairs with the NSABP Foundation. I am a Board Certified Medical Oncologist who specializes in breast cancer and sees patients at the Women’s Cancer Center in Magee-Women’s Hospital of UPMC. .
For my complete bibliography, Click Here.
Selected Publications:
Pogue-Geile KL, Song N, Jeong JH, Gavin PG, Kim SR, Blackmon NL, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S. Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial. Journal of Clinical Oncology. 2015; 33(12): 1340-7.
O'Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmens E, Azambuja E, Piccart-Gebhard M, Zujewski JA, Gelber RD. Efficacy of Adjuvant Trastuzumab for patients with human epidermal growth factor receptor 2-positive early brest cancer and tumors < 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. Journal of Clinical Oncology. 2015; 33(24): 2600-8.
Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer GP. Trastuzumab Plus Adjuvant Chemotherapy for Human epidermal Growth Factor Receptor 2-positive Breast Cancer: Planed Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology. 2014; 32(33): 3744-52.
Romond EH, Rastogi PQ, Jeong JH. Reply to V. Pitini et al. Journal of Clinical Oncology. 2013; 31(17): 225.
Swain SM,, Tang G, Geyer CE Jr, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azaar CA, Robidous A, Polikoff JA, Brufsky AM, Gibbs DD, Levine EA, Zapas JL, Provencher L, Northfelt DW. Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Operable, Node-Positive Breast Cancer:. Journal of Clinical Oncology. 2013; 31(26): 3197-3204.
Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky A, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margoles RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer: NSABP B-40. New England Journal of Medicine. 2012; 366(4): 310-320.
Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, Rathi V, Fehrenbacher L, Brufsky A, Azar CA, Flynn PJ, Zapas JL, Polikoff J, Gross HM, Gibbs DD, Atkins JH, Tan-Chiu E, Zheng P, Yothers G, Mamounas EP, Wolmark N. Follow-Up assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus trastuzumab as Adjuvant Therapy for Patients with Node-Positive, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Clinical Oncology. 2012; 30(31): 3792-3799.
Swain SM, Joeng JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins NJ, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. New England Journal of Medicine. 2010; 362(22): 2053-2065.
Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. Journal of Clinical Oncology. 2008; 26(5): 778-785.
Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon R, Swain S, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophophamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. Journal of Clinical Oncology. 2005; 23(31): 7811-7819.
Notable Achievements
Malcolm E Switzer MD Award, 1992
Harvy Clayton Brill and Stalzer Scholarships, 1992
Golden Key Nation Honor Society, Vice President, 1992-1993
Miami Medicine Honorary Program, 1992-1993
Miami Medicine Honarary Program, Co-President, 1992-1993
Gamma Theta Pi Chemistry Honarary Society, 1992-1993
Sandoz Award, Recognition for outstanding student in Psychiatry, 1996
Dr. Anni Yee Johnson Memorial Award, Presented to the resident who exemplified qualities of thoroughness, motivation, caring, campassion, efficiency and professionalism, 2000
Resident of the Year Award, 2000
Honored Member Strathmore's Who's who, 2004-2005